Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Herbal extract eases IBS pain and bloating in small study

NCT ID NCT07576634

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a standardized Boswellia extract (a herbal supplement) combined with patient education could reduce symptoms of irritable bowel syndrome (IBS) like belly pain, bloating, and irregular bowel habits. Sixty adults with moderate IBS took the extract twice daily for 30 days and attended educational sessions on managing their condition. Researchers tracked symptoms and quality of life over one month to see if the approach helped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

60 people

The number who actually took part.

Started

Jan 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults diagnosed with irritable bowel syndrome (IBS) according to Rome III and Rome IV criteria Recurrent abdominal pain occurring at least once weekly during the preceding three months Presence of changes in stool frequency, stool form, or defecation associated with abdominal pain Participants reporting bloating as the primary symptom Exclusion Criteria: Adherence to special diets (low-fat, lactose-free, or gluten-free diets) within the past six months Food allergies such as soy, nuts, or seafood allergies Insulin-dependent diabetes mellitus Celiac disease Inflammatory bowel disease History of major gastrointestinal surgery, including colonic surgery or cholecystectomy Bloody diarrhea, hematochezia, or melena Recent antibiotic use Presence of alarming gastrointestinal symptoms Severe renal disease Severe hepatic disease Pregnancy Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mansoura University

    Al Mansurah, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.